S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000967704.23014.16 |
| _version_ | 1797281646079115264 |
|---|---|
| author | Efstathios Kastritis Giovanni Palladini Meletios A. Dimopoulos Arnaud Jaccard Giampaolo Merlini Foteini Theodorakakou Despina Fotiou Monique C. Minnema Minnema Ashutosh Wechalekar Elena Papachristou Kyriaki Manousou Pieter Sonneveld Stefan Schönland |
| author_facet | Efstathios Kastritis Giovanni Palladini Meletios A. Dimopoulos Arnaud Jaccard Giampaolo Merlini Foteini Theodorakakou Despina Fotiou Monique C. Minnema Minnema Ashutosh Wechalekar Elena Papachristou Kyriaki Manousou Pieter Sonneveld Stefan Schönland |
| author_sort | Efstathios Kastritis |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:59:24Z |
| format | Article |
| id | doaj.art-d89cfc6d848247d48726e4c02f808abb |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:59:24Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-d89cfc6d848247d48726e4c02f808abb2024-03-03T03:25:45ZengWileyHemaSphere2572-92412023-08-017e230141610.1097/01.HS9.0000967704.23014.16202308003-00100S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORKEfstathios Kastritis0Giovanni Palladini1Meletios A. Dimopoulos2Arnaud Jaccard3Giampaolo Merlini4Foteini Theodorakakou5Despina Fotiou6Monique C. Minnema Minnema7Ashutosh Wechalekar8Elena Papachristou9Kyriaki Manousou10Pieter Sonneveld11Stefan Schönland121 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece2 Amyloidosis Research and Treatment Center, University of Pavia, Pavia, Italy1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece3 Referral Center for AL Amyloidosis, Limoges, France2 Amyloidosis Research and Treatment Center, University of Pavia, Pavia, Italy1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece4 Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands5 Clinical Haematology, Cancer Division, University College London Hospital, London, UK6 Health Data Specialists, Dublin, Ireland6 Health Data Specialists, Dublin, Ireland7 Erasmus MC Cancer Institute, Rotterdam, Netherlands8 University of Heidelberg, Heidelberg, Germanyhttp://journals.lww.com/10.1097/01.HS9.0000967704.23014.16 |
| spellingShingle | Efstathios Kastritis Giovanni Palladini Meletios A. Dimopoulos Arnaud Jaccard Giampaolo Merlini Foteini Theodorakakou Despina Fotiou Monique C. Minnema Minnema Ashutosh Wechalekar Elena Papachristou Kyriaki Manousou Pieter Sonneveld Stefan Schönland S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK HemaSphere |
| title | S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_full | S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_fullStr | S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_full_unstemmed | S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_short | S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_sort | s198 efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis a phase 2 study by the european myeloma network |
| url | http://journals.lww.com/10.1097/01.HS9.0000967704.23014.16 |
| work_keys_str_mv | AT efstathioskastritis s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT giovannipalladini s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT meletiosadimopoulos s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT arnaudjaccard s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT giampaolomerlini s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT foteinitheodorakakou s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT despinafotiou s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT moniquecminnemaminnema s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT ashutoshwechalekar s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT elenapapachristou s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT kyriakimanousou s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT pietersonneveld s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT stefanschonland s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork |